Navigation Links
RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
Date:4/11/2008

n addition to closing on Fund II, RiverVest Venture Partners announced that John P. McKearn, Ph.D., has joined the firm as Venture Partner.

Dr. McKearn brings 25 years of scientific and operational expertise in pharmaceutical research and development at Kalypsys, Inc., Pharmacia, G.D. Searle & Co., and E.I. DuPont de Nemours and Company.

"We've known John since Pfizer bought Pharmacia back in 2003 and have kept in close contact ever since," said Mr. Schmelter. "John's strong scientific training and operational expertise will further our capabilities in sourcing and adding value to our biopharmaceutical portfolio."

While leading Kalypsys, Inc., a privately held biotechnology company in San Diego, Dr. McKearn raised more than $150 million in private equity from 2003-2006. As head of Research for Searle and Pharmacia, Dr. McKearn was an important contributor to the discovery, development and launch of no fewer than eight new prescription drugs, including Celebrex, one of the leading pharmaceuticals to treat arthritis.

"I believe in the quality of RiverVest's personnel, investors and portfolio, along with their vast industry and academic networks," said Dr. McKearn. "Fund I has had an impressive track record, and I look forward to applying my expertise to building RiverVest's biopharmaceutical presence."

Dr. McKearn holds a Ph.D. in immunology from the University of Chicago and a B.S. in biology from Northern Illinois University. He currently serves as a member of the board of directors for IDM Pharma (formerly Epimmune) and for Keel Pharmaceuticals.

About RiverVest Venture Partners

RiverVest Venture Partners is a venture capital firm investing in promising life sciences companies nationwide. RiverVest applies both its capital and its team's diverse range of expertise to create and grow successful enterprises that address unmet medical needs in major markets. RiverVest's extensive national network and privileged access to
'/>"/>

SOURCE RiverVest Venture Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Biopure Gives Update on Malaysia Joint Venture Discussions
3. Hank Plain Joins Morgenthaler Ventures as Partner
4. Dan Broderick Joins Prolog Ventures as Partner
5. DiObex Inc. to Present at BIO Mid-America Venture Forum
6. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
7. Altheus Therapeutics Secures $3.6 Million in Venture Capital
8. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
9. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)... -- PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in New York.  Ingo Bank , ... making a presentation on PAREXEL and discussing business developments ... A live webcast of the discussion will ... at www.PAREXEL.com in the Upcoming Events portion ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
Breaking Biology Technology:Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... aTyr Pharma, the physiocrine therapeutics company, today announced ... by Domain Associates.  Domain joins existing venture investors ... also participated in the financing.  Proceeds will be ... pipeline and advance physiocrine drug candidates into clinical ...
... announced that it has successfully modified yeast to be ... encountered in the bioproduction of fuel ethanol. In doing ... more ethanol. "We are very pleased ... developing a 2nd generation with yet better commercial performance ...
... ITHACA, N.Y. The human hand is an amazing ... but for a robot, this "gripping" mechanism is a vexing ... of Chicago and iRobot have bypassed traditional designs based around ... using everyday ground coffee and a latex party balloon. ...
Cached Biology Technology:aTyr Pharma Secures $23M Financing From Top Tier Venture Investor 2iDiverse Develops Stress Resistant Yeast for Producing Fuel Ethanol 2Robotic gripper runs on coffee ... and balloons 2
(Date:8/20/2014)... 20, 2014 George E. Fox, a John and Rebecca ... Houston (UH), was named a fellow in the International Society ... , Fox is one of four members two from ... chosen as fellows in 2014. Fellows are elected every three ... than 500 members from more than 20 countries, the ISSOL ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... /CNW/ -  Issue Serious allergic reactions ... life threatening for some children.    What you ... have food allergies and this number may be increasing, especially ... estimated to have food allergies.  The symptoms ... hives to breathing difficulties and loss of consciousness. Symptoms can ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... underfunding health: so what kind of new development paradigm will ... and where will sexual and reproductive health and rights (SRHR) ... latest themed issue of Reproductive Health Matters explore ... at the global policy level, and the evolution of the ...
... 9, 2013) A new study shows that high school ... closer to sea-level, a phenomenon attributed to physiological changes in ... skull. "This is the first time any research has ... professor of epidemiology at the Colorado School of Public Health ...
... , Dec. 9, 2013 Today, the country,s ... a Series D extension of $15 million in new ... its venture capital arm, Qualcomm Ventures, brings Practice Fusion,s ... raised to date at $149 million. The round was ...
Cached Biology News:Reproductive Health Matters announces publication of its latest themed issue: New development paradigm 2Study shows first link between altitude and concussion 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 3
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Catalase (Control)...
Biology Products: